Clinical trials: Idiopathic Lung Fibrosis
Idiopathic Pulmonary Fibrosis
A Phase II Study to Evaluate the Efficacy and Safety of SYH2059 Tablets in Adult Patients With Idiopathic Pulmonary Fibrosis
This is a multicenter, randomized, double-blind, placebo-controlled Phase II study. It Aims aims to evaluate the efficacy and safety of different doses of SYH2059 tablets compared with placebo in adult patients with IPF, observe…
- Trial name
- NCT07600021
- Testing
- SYH2059 Tablets
- Volunteers
- 156 people
- Sponsor
- InnovStone Therapeutics Limited
Interstitial Lung Disease
Interstitial Lung Diseases in the Veterans Administration
The primary objective of this research project is to describe the characteristics, diagnosis, management, and outcomes of patients with Interstitial Lung Disease (ILD) who received care at the Veteran's Administration Veterans…
- Trial name
- NCT02479126
- Where
- United States
- Volunteers
- 3,000 people
- Sponsor
- Robert Tighe
Idiopathic Pulmonary Fibrosis
Evaluation of Patients With Idiopathic Pulmonary Fibrosis (IPF) Through an IPF Registry
The purpose of this study is to create a database of demographics and samples in idiopathic pulmonary fibrosis.
- Trial name
- NCT00212511
- Where
- United States
- Sponsor
- NYU Langone Health
Pulmonary Alveolar Proteinosis, COPD
Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection
COVID-19 Viral Global Pandemic resulting in post-infection pulmonary damage, including Fibrotic Lung Disease due to inflammatory and reactive protein secretions damaging pulmonary alveolar structure and functionality.
- Conditions
- Pulmonary Alveolar Proteinosis, COPD, Idiopathic Pulmonary Fibrosis, Viral Pneumonia
- Trial name
- GARM-COVID19 (NCT04326036)
- Testing
- Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF), Centricyte 1000, IV Deployment Of cSVF In Sterile Normal Saline IV Solution
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Black Tie Medical, Inc.
Idiopathic Pulmonary Fibrosis
A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)
The investigators will conduct a single-center, prospective, randomized, placebo-controlled, double-blind pilot study of anti-herpesvirus therapy in patients with idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT02871401
- Testing
- Valganciclovir
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Vanderbilt University Medical Center
Idiopathic Pulmonary Fibrosis (IPF)
A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
This study is a multicentre, randomised, double-blind, placebo-controlled, adaptive design clinical trial to evaluate the efficacy and safety of TDI01 suspension in the treatment of idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT07464912
- Testing
- TDI01
- Where
- China
- Volunteers
- 508 people
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
Idiopathic Pulmonary Fibrosis (IPF)
D Vitamin and Alveolar Macrophages in Idiopathic Pulmonal Fibrosis
The goal of this observational study is to gain deeper insights into human macrophages and vitamin D, and their interplay, within Idiopathic Pulmonary Fibrosis (IPF).
- Trial name
- NCT06909409
- Where
- Denmark
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
IPF
Combined PEX, Rituximab and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations
This is an open-label Phase I/II trial to assess the feasibility and safety of combined plasma exchange (PEX), rituximab, and conventional corticosteroid administration on the outcome of hospitalized patients with acute IPF…
- Trial name
- NCT01266317
- Testing
- Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Michael Donahoe
Idiopathic Pulmonary Fibrosis
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT05671835
- Testing
- TTI-101
- Where
- 28 sites in United States
- Volunteers
- 100 people
- Sponsor
- Tvardi Therapeutics, Incorporated
Fibrosis, Pulmonary
Inspiratory Effort Assessed Through Nasal Pressure Measurement in Patients With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF) is a fibrosing progressive interstitial lung disease with unknown etiology, with a median survival of 3 years since first diagnosis.
- Trial name
- NASA (NCT05310669)
- Testing
- Nasal pressure assessment
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- University of Modena and Reggio Emilia
Interstitial Lung Diseases
Monitoring and Evaluation Study of Project ECHO for ILD
The study will utilize pre-post survey measures to evaluate Project ECHO for ILD with respect to an initial set of practice and clinical outcomes and relies on questionnaire data obtained from providers participating in Project…
- Trial name
- NCT05455437
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Pulmonary Care and Research Collaborative Limited
Idiopathic Pulmonary Fibrosis
Inhalation Profiling of Idiopathic Pulmonary Fibrosis (IPF) Patients
This is a clinical study to characterise the lung function, airway morphometry, pharyngometry and inhalation profiles in patients with mild to severe Idiopathic Pulmonary Fibrosis (IPF) over a period of up to 6 months.
- Trial name
- NCT02058602
- Testing
- Assessment of Idiopathic Pulmonary Fibrosis over a period of up to 6 months
- Where
- Belgium
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis, Ankylosing Spondylitis
PatientSpot Formerly Known as ArthritisPower
Patient Power is a patient research network and database (registry) to collect prospective information about demographics, self-reported diagnoses and medications, and willingness to participate in research from participants with…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout
- Trial name
- NCT03840928
- Where
- United States
- Volunteers
- 40,000 people, healthy volunteers welcome
- Sponsor
- Global Healthy Living Foundation
Idiopathic Pulmonary Fibrosis
A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
This study is open to adults with idiopathic pulmonary fibrosis (IPF) who are at least 40 years old. People taking standard medicines for IPF, including antifibrotic medicines, can continue taking them throughout the study.
- Trial name
- NCT04419506
- Testing
- BI 1015550
- Where
- 75 sites in United States, Argentina and 20 more
- Volunteers
- 147 people
- Sponsor
- Boehringer Ingelheim
Fibrosis, Inflammation
A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of RXC007.
- Conditions
- Fibrosis, Inflammation, Idiopathic Pulmonary Fibrosis, Non-alcoholic Steatohepatitis
- Trial name
- NCT04931147
- Testing
- RXC007
- Where
- United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Redx Pharma Ltd
Rheumatoid Arthritis, Interstitial Lung Disease
Tofacitinib in the Treatment of Rheumatoid Arthritis-related Interstitial Lung Disease.
Nowadays, no single drug is approved to treat rheumatoid arthritis-related interstitial lung disease (RA-ILD). The medical management of this clinical condition is empirical and controversial.
- Trial name
- RAILDTo (NCT05246293)
- Testing
- Tofacitinib
- Where
- Mexico
- Volunteers
- 60 people
- Sponsor
- National Institute of Respiratory Diseases, Mexico
Idiopathic Pulmonary Fibrosis
Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF).
This study is a national, multicenter, interventional, non-randomized, non-controlled, open-label study to assess the effectiveness of pirfenidone in participants with IPF in Russian clinical practice.
- Trial name
- NCT03208933
- Testing
- Pirfenidone
- Where
- 11 sites in Russia
- Volunteers
- 60 people
- Sponsor
- Hoffmann-La Roche
Idiopathic Pulmonary Fibrosis
Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)
The primary objectives of this study are to determine the effect of simtuzumab (GS-6624) on progression-free survival (PFS) as determined by either a categorical decline in forced vital capacity (FVC) or all-cause mortality, in…
- Trial name
- RAINIER (NCT01769196)
- Testing
- Simtuzumab
- Where
- 175 sites in United States, Australia and 12 more
- Volunteers
- 544 people
- Sponsor
- Gilead Sciences
Idiopathic Pulmonary Fibrosis
Detection of Early Idiopathic Pulmonary Fibrosis
The purpose of the study is to determine if miR200 family may serve as a biomarker of IPF.
- Trial name
- NCT03457935
- Testing
- blood samples
- Where
- United States
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Temple University
Idiopathic Pulmonary Fibrosis, Lung Diseases, Interstitial
Idiopathic Pulmonary Fibrosis and Serum Bank
Idiopathic pulmonary fibrosis (IPF) is the most common form of chronic idiopathic diffuse interstitial lung disease (DILD) in adults.
- Trial name
- FPI (NCT04016168)
- Testing
- Blood sample collection
- Where
- France
- Volunteers
- 903 people
- Sponsor
- Rennes University Hospital